2014 Press Releases
With Accreditation Hebrew SeniorLife Hospice Care Opens Doors to Patients in Greater Boston
New England’s preeminent senior care provider adds hospice to its comprehensive continuum of health care services
BOSTON – Harvard Medical School-affiliated Hebrew SeniorLife (HSL), the largest provider of senior health care and senior living communities in New England, announced today that Hebrew SeniorLife Hospice Care has earned accreditation from CHAP (Community Health Accreditation Program). CHAP is an independent, nonprofit accrediting body for community-based health care organizations authorized by Medicare to survey hospice organizations. With accreditation, services provided by HSL Hospice Care are now broadly available to seniors in Greater Boston.
Hebrew SeniorLife Names Todd Finard as Chair of Board of Directors
Young Boston Business Leader Leverages Deep Family Experience to Bring New Attention to Issues of Senior Care
BOSTON – Hebrew SeniorLife (HSL), the largest provider of senior health care and senior living communities in New England, has named Todd Finard as Chair of the organization’s Board of Directors. Todd has been a devoted volunteer leader at HSL for almost 20 years, having recently served on the HSL Board as Chair Elect and on the Governance and Development Committees, and previously as President of the Friends of Hebrew SeniorLife.
Research Sheds New Light on Heritability of Disease
Study explores the role DNA plays to predispose individuals to diseases such as type 2 diabetes
BOSTON - A group of international researchers, led by a research fellow in the Harvard Medical School-affiliated Institute for Aging Research at Hebrew SeniorLife, published a paper today in Cell describing a study aimed at better understanding how inherited genetic differences, or variants, predispose certain individuals to develop diseases such as type 2 diabetes. The study integrated computational methodology with experimentation to address and prove underlying genetic causes of type 2 diabetes. In principle, the new methodology can be applied to any common disease, including osteoporosis, Alzheimer’s disease and cancer. The hope is that with better understanding of how DNA functions in these individuals, new treatments will follow.